Top Markets
Coin of the day
ViewRay, Inc. ViewRay, Inc.

ViewRay, Inc.

VRAY
Rang în acțiuni #37058
ViewRay, Inc. specializes in the development, production, and global... ViewRay, Inc. specializes in the development, production, and global distribution of advanced radiation therapy systems that leverage magnetic resonance imaging (MRI). These integrated systems are utilized to both image and deliver treatment for cancer patients in various countries, including the United States, France, Taiwan, and the United Kingdom. The company's key product, MRIdian, is an MRI-guided radiation therapy solution engineered to address critical concerns during treatment, such as beam distortion and potential skin toxicity. ViewRay's client base spans a diverse range of medical facilities, including university research and teaching hospitals, local community hospitals, private medical practices, government institutions, and independent cancer treatment centers. MRIdian systems are sold to these clients via ViewRay's direct sales force and through its established distribution channels. The company was founded in 2004 and operates out of its main office in Oakwood, Ohio.
Preț acțiune
$0.014
Ultima sincronizare: 2023-08-21
Capitalizare de piață
$2.07M
Schimbare (1 zi)
-1.41%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează ViewRay, Inc. (VRAY)

Categorie

Venituri pentru ViewRay, Inc. (VRAY)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale ViewRay, Inc., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru ViewRay, Inc. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
$6.51B -
US